5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Chi, K. N.; Vaishampayan, U.; Hotte, S.; Vogelzang, N.; Alumkal, J.; Agrawal, M.; Nydam, T. M.; Fandi, A.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Meeting Abstract

    Reid, A. H.; Attard, G.; Danila, D.; Ryan, C. J.; Thompson, E.; Kheoh, T.; Molina, A.; Small, E.; Scher, H.; De-Bono, J. S.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I/II study of docetaxel and (153)Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Rathkopf, D.; Solit, D.; Carrasquillo, J.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Molina, A. M.; Tickoo, S. K.; Ishill, N.; Trinos, M. J.; Schwartz, L. H.; Russo, P.; Feldman, D. R.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies
    Meeting Abstract

    Mitsiades, N.; Schultz, N.; Taylor, B. S.; Hieronymus, H.; Satagopan, J.; Scardino, P. T.; Reuter, V. E.; Sander, C.; Sawyers, C.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Correlation of dynamic contrast enhanced magnetic resonance imaging (DCE MRI) with (18)f-fluoromisonidazole positron emission and computed tomography ((18)F-FMISO PET/CT) in assessing tumor hypoxia in a series of head and neck cancer (HNC) patients with nodal metastases
    Meeting Abstract

    Lee, N.; Jensen, J.; Schoder, H.; Wang, Y.; Fury, M.; Pfister, D. G.; Stambuk, H.; Humm, J.; Koutcher, J.; Shukla-Dave, A.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial
    Meeting Abstract

    Lin, J.; Beer, T. M.; Ryan, C. J.; Mathew, P.; Wilding, G.; Morris, M.; Callahan, J. A.; Gordon, G.; Reich, S.; Carducci, M. A.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Kroog, G. S.; Feldman, D. R.; Kondagunta, G. V.; Ginsberg, M. S.; Fischer, P. M.; Trinos, M. J.; Patil, S.; Ishill, N. M.; Motzer, R. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Prevention of hip fractures in older men receiving androgen deprivation therapy for prostate cancer: A cost-effectiveness analysis
    Meeting Abstract

    Ito, K.; Elkin, E.; Morris, M.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save